| 辛中帅,张彦彦,晋小雁,杨建红.我国已上市治疗用重组蛋白多肽类产品分析[J].中国药事,2019,33(9):991-997 |
| 我国已上市治疗用重组蛋白多肽类产品分析 |
| Analysis of Listed Recombinant Protein or Peptide Products for Therapeutic Use in China |
| 投稿时间：2019-08-01 |
| DOI：10.16153/j.1002-7777.2019.09.005 |
| 中文关键词: 生物制品 重组蛋白多肽 已上市药品 技术分析 |
| 英文关键词: biological product recombinant protein or peptide listed drugs technical analysis |
| 基金项目: |
|
| 摘要点击次数: 1063 |
| 全文下载次数: 628 |
| 中文摘要: |
| 目的：找出我国治疗用重组蛋白多肽类产品存在的不足，明确未来努力方向。方法：基于我国已上市治疗用重组蛋白多肽类产品批准数据进行统计分析和对比分析。结果：对我国已上市的重组蛋白多肽类产品的基本情况、技术代次、治疗领域等进行了回顾梳理。结论：我国重组蛋白多肽类药物在新一代产品的开发上，由于企业创新不足及技术落后，与国际先进水平的差距近年来在进一步加大。 |
| 英文摘要: |
| Objective:To find out the shortcomings of recombinant protein or peptide products for therapeutic use in China and determine the future direction. Methods:Based on the approval data of recombinant protein or peptide products in China, the statistical analysis and comparative analysis were conducted. Results:The basic situation, technical generation and therapeutic field of the recombinant protein or peptide drugs listed in China were reviewed and analyzed. Conclusion:Due to the lack of innovation and backward technology in the development of new generation products, the gap between recombinant protein or peptide drugs and the international advanced level has been further widened in recent years. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |